ClinicalTrials.Veeva

Menu

Prediction of MMSE Scores for Cognitive Impairment

B

Blekinge Institute of Technology

Status

Completed

Conditions

Healthy Control
Cognitive Impairment

Treatments

Other: MMSE ≤26

Study type

Observational

Funder types

Other

Identifiers

NCT06611475
BTH-6.1.1-0156-2024

Details and patient eligibility

About

This study aims to explore the potential of using machine learning (ML) algorithms to predict cognitive status, specifically MMSE scores, based on oral health and demographic data. The objective is to evaluate the effectiveness of various ML models and identify the most relevant oral health indicators for predicting MMSE scores of 30 (normal cognition) or ≤26 (cognitive impairment) in individuals aged 60 and above.

Full description

This cross-sectional study utilizes oral health and demographic data from two existing cohort studies: the European collaborative study Support Monitoring and Reminder Technology for Mild Dementia (SMART4MD) and the Swedish National Study on Aging and Care (SNAC-B). Participants aged 60 years or older will be included in the analysis. The data will be used to develop and evaluate machine learning models for predicting cognitive status.

Objectives:

  1. Primary Objective: To assess the potential of oral health parameters for binary classification of MMSE scores (30 vs. ≤26).
  2. Secondary Objective: To identify the most influential oral health parameters contributing to cognitive impairment predictions.
  3. Tertiary Objective: To compare the performance of Random Forest (RF), Support Vector Machine (SVM), and CatBoost (CB) classifiers in predicting MMSE scores using oral health data.

Enrollment

693 patients

Sex

All

Ages

60+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Individuals aged 60 years or older.
  • Participants with recorded oral health parameters and MMSE scores of either 30 or ≤26.

Exclusion criteria

  • Individuals with MMSE scores of 27, 28, or 29, as these scores represent a transition phase between normal cognition and cognitive impairment, which could introduce variability.
  • Individuals younger than 60 years.

Trial design

693 participants in 2 patient groups

MMSE ≤26
Description:
339 participants
Treatment:
Other: MMSE ≤26
MMSE 30
Description:
354 participants
Treatment:
Other: MMSE ≤26

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems